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More than 20 million babies are born with low birthweight annually. Small newborns have an
increased risk for mortality, growth failure, and other adverse outcomes. Numerous antenatal risk fac-
tors for small newborn size have been identified, but individual interventions addressing them have
not markedly improved the health outcomes of interest. We tested a hypothesis that in low‐income
settings, newborn size is influenced jointly by multiple maternal exposures and characterized path-
ways associating these exposures with newborn size. This was a prospective cohort study of pregnant
women and their offspring nested in an intervention trial in rural Malawi.We collected information on
maternal and placental characteristics and used regression analyses, structural equationmodelling, and
random forest models to build pathway maps for direct and indirect associations between these
characteristics and newborn weight‐for‐age Z‐score and length‐for‐age Z‐score. We used multiple
imputation to infer values for any missing data. Among 1,179 pregnant women and their babies, new-
born weight‐for‐age Z‐score was directly predicted by maternal primiparity, body mass index, and
plasma alpha‐1‐acid glycoprotein concentration before 20weeks of gestation, gestational weight gain,
duration of pregnancy, placental weight, and newborn length‐for‐age Z‐score (p < .05). The latter 5
variables were interconnected andwere predicted by several more distal determinants. In low‐income
conditions like rural Malawi, maternal infections, inflammation, nutrition, and certain constitutional
factors jointly influence newborn size. Because of this complex network, comprehensive interventions
that concurrently address multiple adverse exposures are more likely to increase mean newborn size
than focused interventions targeting only maternal nutrition or specific infections.
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Key messages
• In low‐income conditions, maternal infections,
inflammation, nutrition, and other factors jointly
influence newborn size. Because of this complex
network, interventions that address multiple adverse
exposures concurrently are more likely to increase
mean newborn size than the traditional narrowly
focused interventions.
• Infections play a prominent role in predicting newborn
length‐for‐age Z‐score and hence indirectly also
newborn weight‐for‐age Z‐score.
• Holistic prevention and management interventions are
needed to limit the adverse impact of maternal
infections on the duration of pregnancy and foetal
growth in low‐income settings.Of the approximately 135 million infants born each year, 16% (22 mil-
lion) are born small, as indicated by a low birthweight (<2.5 kg; UNICEF,
2014). These babies have an increased risk of mortality, malnutrition,
growth failure, and developmental delay in childhood and adverse
health consequences in adult life (Christian et al., 2013; Katz et al.,
2013; Lawn, Cousens, Zupan, & Lancet Neonatal Survival Steering
Team, 2005). Therefore, prevention of low birthweight and small birth
size is considered a public health priority, especially in the sub‐Saharan
African and South Asian low‐income countries where their incidence is
highest (UNICEF, 2014).
A small birth size can result either from a preterm birth or a
restricted foetal growth velocity or a combination of these two. Both
conditions are common in low‐income settings (Lee et al., 2013) and
associated with such risk factors as maternal undernutrition, inflamma-
tion, and stress and with infections including malaria, HIV, and repro-
ductive tract infections (Brodsky & Christou, 2004). Typical
interventions to improve birth size have therefore included maternal
dietary supplementation and infection treatment in pregnancy.
Although some positive results have been reported from such
interventions, the effect sizes have been modest, and many studies
have reported no impact at all (Bhutta et al., 2013). One possible expla-
nation for this limited success is narrowness of scope, that is, that
research trials have addressed only one, or at maximum a few, of the
putative risk factors. This approach assumes a single dominant
aetiology for small birth size, but a co‐causation model is arguably
more plausible, especially in low‐income contexts where infections,
undernutrition, and other adverse exposures are often common among
pregnant women. So far, however, there have been few studies that
have concurrently analyzed multiple maternal risk factors and their
joint contribution to birth size.
To characterize the determinants of birth size in a low‐income
context, we carried out a large prospective study in rural Malawi, in
which we collected information on maternal, foetal, placental, and
newborn health at several points of pregnancy and thereafter. Using
regression analysis, structural equation modelling (SEM), and random
forest techniques, we built a concept map to characterize and
illustrate the network of pathways connecting maternal constitutional
variables, infection, inflammation, nutrition, stress, and the duration of
pregnancy with newborn size. Because of its public health implica-
tions, we used newborn weight as the main outcome but also included
newborn length in our models, to separate the contributions of foetal
linear growth and fat and lean tissue deposition to the outcome of
interest.2 | METHODS
2.1 | Study design and general context
This was a prospective cohort study, nested within a randomized,
outcome assessor‐blinded intervention trial in rural Malawi, carried
out between February 2011 and April 2015 in an area with
frequent maternal infections and a high prevalence of preterm birthand low birthweight (Ashorn, Alho, Ashorn, Cheung, Dewey,
Gondwe, et al., 2015a; Luntamo et al., 2010). The original trial
was designed to study the impact of small‐quantity lipid‐based
nutrient supplements on maternal and child outcomes, when pro-
vided to women in pregnancy (enrolment <20 gestation weeks)
and during the first 6 months of lactation and their newly born
children from 6 to 18 months of age. In the embedded cohort study
described in this article, we characterized the direct and indirect
associations between selected maternal characteristics and newborn
size, focusing on pathways that lead to reduced weight or length in
the newborn.
According to the main results of this trial, named iLiNS‐DYAD‐M,
provision of small‐quantity lipid‐based nutrient supplements to women
in pregnancy and the first 6 months of lactation and to their children
from 6 to 18 months of age was not associated with improved birth
outcomes or child length or weight at 18 months of age (Ashorn, Alho,
Ashorn, Cheung, Dewey, Gondwe, et al., 2015a; Ashorn, Alho, Ashorn,
Cheung, Dewey, Harjunmaa, et al., 2015b).
The trial was performed according to Good Clinical Practice
guidelines and the ethical standards of the Helsinki Declaration. The
protocol was approved by the College of Medicine Research and Ethics
Committee, University of Malawi and the Ethics Committee of
Pirkanmaa Hospital District, Finland, and it was registered at the
clinicaltrials.gov database (registration number NCT01239693). Only
participants who signed or thumb‐printed an informed consent form
were enrolled in the study.
For the currently described cohort study, we included all new-
borns who participated in the main trial, except twins and infants
who had no postnatal anthropometric measurements.2.2 | Variables used for the models
Webased our pathwaymaps on a conceptualmodel, according towhich
maternal exposures (defined as predictor variables) could contribute to
newborn size either directly or through intermediary variables that
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category included variables that described maternal characteristics in
early pregnancy or the woman's direct exposures during the follow‐up
(e.g., maternal nutrition or infection), whereas the intermediary vari-
ables were those that would follow from a primary exposure. The
predictor and intermediate variables were selected either based on
earlier literature (Brodsky & Christou, 2004) or because our own initial
analyses had documented an association between them and newborn
size (Harjunmaa et al., 2015; Stewart et al., 2015).
The variables in the predictor category covered maternal constitu-
tion and obstetric history (maternal age and height at enrolment and
primiparity), maternal nutritional status (body mass index [BMI] and
blood haemoglobin concentration), and maternal infections (HIV,
peripheral bloodmalaria parasitemia at enrolment, and dental periapical
infections, urinary tract infections, vaginal trichomoniasis, placental
malaria, and severe chorioamnionitis at delivery or soon thereafter).
Because newborn weight and length were measured soon after birth
but not at birth (mean age 13 days), the delivery method (which may
affect length immediately after birth) would be unlikely to affect them.
Similarly, there would be little variation in feeding types at that point.
Hence, we did not include the delivery mode or infant feeding variables
in our models.
As intermediary variables, we selected plasma alpha‐1‐acid glyco-
protein (AGP) concentration at enrolment as a sign of inflammation,
salivary cortisol concentration at 28 gestation weeks as a sign of
maternal stress, maternal weight gain during pregnancy, placental
weight, and the duration of pregnancy (established using obstetric
ultrasounds before 20 gestation weeks). For the size outcomes, we
studied newborn weight‐for‐age Z‐score (WAZ) and length‐for‐age
Z‐score (LAZ), measured at the latest by 6 weeks after birth. We were
interested in weight because it predicts childhood wasting andFIGURE 1 Conceptual model of pathways contributing to newborn size.
exposures during follow‐up (defined as predictor variables) could contribu
[WAZ] and length‐for‐age Z‐score [LAZ]) either directly or through interme
AGP = α‐1‐acid glycoprotein; BMI = body mass indexmortality (Katz et al., 2013), and length both because it is a determi-
nant of newborn weight and because it predicts childhood stunting,
the reduction of which is a recent World Health Organization target
(de Onis et al., 2013; Espo et al., 2002). To describe and visualize
the predictors of newborn length (linear growth) and “robustness”
(ponderal growth) and their contribution to newborn weight separately,
we included LAZ in the models and concept maps for newborn WAZ.
To establish and document the independent contribution of the dura-
tion of pregnancy on newborn size, we entered the duration as one
variable and expressed the anthropometric indexes unadjusted to the
duration of pregnancy—that is, we used the World Health Organization
growth standard that adjusts for postnatal age but not for the duration
of pregnancy, rather than the newer Intergrowth‐21st standard that
adjusts birth size for pregnancy duration but not for postnatal age.
We assessed newborn anthropometrics at a clinic visit
1–6 weeks after delivery, rather than immediately at birth. This
choice was motivated by the difficulty of accurately measuring
length soon after birth and because a number of participants
delivered at home, where length measurement would have been
logistically difficult. To adjust the newborn size data for age at
measurement (and for newborn sex), we calculated anthropometric
indices (WAZ and LAZ) and used them in our models, instead of
raw weight and length values (WHO Multicentre Growth Reference
Study Group, 2006).
Further details of the data collection are provided in Data S1.2.3 | Statistical analyses
We started the analysis by establishing the bivariate associations
(p < .05) between the predictor and intermediary variables that weConceptual model of how maternal characteristics or maternal direct
te to newborn size (outcome variables weight‐for‐age Z‐score
diary variables that follow from a direct exposure. Hb = haemoglobin;
4 of 10 ASHORN ET AL.
bs_bs_banneranticipated to be associated with newborn WAZ and LAZ. We then
built regression models for newborn WAZ and LAZ, adding multiple
variables into the models one‐by‐one, with the perceived most distal
predictor variables first and most proximal intermediary ones last. To
identify potential indirect pathways, we built similar multivariable
regression models also for each of the predictor and intermediary var-
iables. Based on results from these regression models, we then created
a graphic illustration for direct and indirect pathways contributing to
newborn WAZ and LAZ. Finally, we made comparisons on how the
various categories of predictor variables were associated with new-
born WAZ or LAZ.
We imputed missing data for predictor variables and intermediary
variables as well as outcome variables that were measured after
6 weeks from delivery. We used multiple imputed data (50 imputa-
tions) based on chained equation methods, for all ordinary least‐
squares regression and logistic regression analyses. Among the
included participants for regression analyses, the number of originally
missing values that were substituted with values obtained by multiple
imputation ranged from 0 to 480 (0.0% to 34.8%) per variable
(Supplementary Table 1).
We estimated regression coefficients for continuous variables and
odds ratios for dichotomous variables when estimating associations
between variables in bivariate and multivariable models. We did not
use normalization procedures for any variables because parametric
analysis of means is robust and valid in case of a large sample size,
regardless of the shape of outcome distribution as per the central limit
theorem (Cheung, 2014). All models including salivary cortisol concen-
tration were adjusted for time since waking up and time since last meal
or drink. The intervention provided during pregnancy was not included
as a covariate in the models because it was not statistically significant,
and adding it in the models did not change the results.
We estimated coefficients for pathway models using SEM that
allowed us to include variables both as endogenous (outcome) and
exogenous (predictor) in the same model. The arrows pointing to the
most central variable (LAZ and WAZ) describe the change in the
outcome (Z‐scores for anthropometric indices). Arrows pointing to
any other continuous variable in the model describe the change in
standardized values (mean 0 and standard deviation [SD] 1).
Continuous exogenous variables were also standardized. The
coefficients of dichotomous exogenous variables are interpreted as
the change in the outcome variable when the value of dichotomous
variable changes from 0 to 1.
We used the maximum likelihood method with missing values
to estimate model parameters in the SEM. We allowed correlation
between all exogenous variables and calculated the χ2 value for
the model. We also estimated three other goodness of fit indices
for each SEM; the root mean square error of approximation
(RMSEA), the comparative fit index (CFI), and the Tucker and
Lewis index (TLI). An RMSEA score of zero indicates a perfect
fit, scores <0.05 are considered markers of a good fit, and scores
≥0.05 and <0.08 are considered to indicate an adequate fit. For
CFI and TLI, values at or above 0.90 are typically considered to
indicate a well‐fitting model. All three goodness of fit indices
adjust for the relative complexity of the model (Hu & Bentler,
1999; Kline, 2011).In SEM, we used only continuous endogenous variables that in
regression analyses were associated (p < .05) with newborn size. We
considered p values below .05 indicative of statistical significance also
in SEM. Because we could not estimate parameters for pathways lead-
ing to the dichotomous variables (maternal malaria, HIV, and
primiparity) with SEM, we established the direction of association from
regression models and indicate the associations with dashed lines in
the pathway graphs.
As a sensitivity analysis to SEM, we used random forest
modelling and forest plots (R Version 3.2.1, number of trees to grow
1,000). We imputed missing values in predictor data using R
software's command rfImpute in random forest and regressed WAZ
and LAZ against all the tested predictor and intermediate variables
and calculated raw variable importance for all predictor and interme-
diate variables.
All statistical analyses were done with either Stata Version 13.0
(StataCorp, College Station, TX, USA) or R Version 3.2.1.3 | RESULTS
Of the 1,391 women who were enrolled into the iLiNS‐DYAD‐M
study, 1,379 (99.1%) provided data for analyses with predictor and
intermediary variables and 1,179 (84.8%) provided data for the analy-
ses also with child anthropometrics. The reasons for exclusion were
twin pregnancy (12 subjects) and lack of any anthropometric informa-
tion for the infant (because of loss of pregnancy, death, or drop‐out;
200 subjects). The included women were less often primiparous than
the excluded ones (19.5% vs. 35.1%). For other baseline characteris-
tics, there were some statistically significant but clinically nonsignifi-
cant differences between the included and excluded participants
(Table 1). Of the newborns, 91 (7.8%) had either length or weight
values estimated by multiple imputation, because the actual values
were collected only after 6 weeks of age. There were no clinically
significant differences in the mean baseline characteristics between
participants with imputed values for anthropometrics or any of the
intermediary variables and participants with no imputed data for these
variables (data not shown).
The mean (SD) age of the infants at size measurement was 13
(6) days. The mean (SD) newborn weight and length were 3.4 (0.5)
kg and 49.7 (2.3) cm, corresponding to a WAZ of −0.56 (1.03) and
LAZ of −1.00 (1.11). Of the babies born, 52.3% were boys, 6.3%
were born preterm (<37.0 gestation weeks), 9.0% had a low new-
born WAZ, and 30.6% were considered small‐for‐gestational age
(Alexander, Himes, Kaufman, Mor, & Kogan, 1996). The mean (SD)
duration of pregnancy at delivery was 39.6 (1.8) weeks, and the
mean (SD) maternal weight gain and placental weight were 290
(100) g/week and 516 (102) g, respectively. Thirteen per cent
(12.5%) of participants had an elevated AGP concentration (>1 g/L)
at enrolment. Twenty‐three per cent (23.4%) had at least one dental
periapical infection, 10.3% had vaginal trichomoniasis, 2.3% had a
urinary tract infection, 11.8% had histologically documented severe
chorioamnionitis, and 38.9% had signs of placental malaria. Mean
maternal cortisol concentration at enrolment was 5.7 nmol/L and
at 28 gestation weeks 5.9 nmol/L.
TABLE 1 Baseline characteristics at study enrolment of iLiNS‐DYAD trial participants who were included in or excluded from the current analysesa
Characteristic Included Excluded pb
Number of participants 1,179 212
Maternal age (years) 25 (6) 24 (6) .002
Maternal education (completed years) 4.0 (3.4) 4.3 (3.7) .340
Severely food insecure households (%) 36.0 35.7 .931
Gestational age (week) 16.8 (2.1) 17.1 (2.1) .084
Number of previous pregnancies 2.2 (1.7) 1.7 (1.8) <.001
Primiparous women (%) 19.5 35.1 <.001
Height (cm) 156.1 (5.7) 155.8 (5.7) .438
Weight (kg) 53.9 (7.9) 55.2 (8.5) .027
MUAC (cm) 26.3 (2.6) 26.6 (2.9) .119
BMI (kg/m2) 22.1 (2.8) 22.7 (2.9) .005
Women with a BMI < 18.5 kg/m2 (%) 5.5 4.7 .667
Blood haemoglobin concentration (g/L) 112 (16) 109 (16) .010
Anaemic women (Hb < 100 g/L; %) 19.8 25.6 .055
Cortisol (nmol/L) 5.7 (2.9) 5.7 (3.8) .811
Mean (SD) AGP (g/L) 0.8 (0.3) 0.7 (0.2) .030
Women with AGP > 1 g/L (%) 12.5 14.1 .550
Women with a positive HIV test (%) 13.4 16.1 .358
Women with positive malaria RDT (%) 22.9 25.0 .500
Note. MUAC = mid‐upper arm circumference; Hb = haemoglobin; AGP = α‐1‐acid glycoprotein; RDT = rapid diagnostic test; BMI = body mass index.
aValues are means ± SD or percentages, unless otherwise indicated.
bThe p value obtained from analysis of variance (continuous variables) or chi‐square test (proportions).
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variables
In multivariable models that included all the tested predictor and inter-
mediary variables, plasma AGP concentration was independently
associated with maternal primiparity, HIV infection, weight gain during
pregnancy, peripheral blood malaria parasitemia at enrolment, and
severe chorioamnionitis (Table 2). Maternal weekly weight gain,
placental weight, and the duration of pregnancy were predicted by
various combinations of the test variables (Table 2). None of the
selected variables predicted maternal salivary cortisol concentration at
28 gestation weeks. These multivariable models explained 5.5–15.4%
of the variance in intermediary variables.3.2 | Multivariable regression models of newborn
weight‐for‐age and length‐for‐age
A multivariable regression model, adjusting for all the predictor vari-
ables, indicated that newborn WAZ was positively associated with
maternal height, BMI, and haemoglobin (Hb) at enrolment and nega-
tively associated with maternal primiparity, HIV infection, malaria,
periapical infections, and urinary tract infection (Table 3, Model 1).
Addition of the potential intermediary outcomes in the model removed
the association with Hb and HIV infection and attenuated other coef-
ficients but not maternal BMI (Table 3, Model 2). Of the intermediary
variables, all but maternal salivary cortisol concentration were associ-
ated with newborn WAZ. Further adjustment with newborn LAZ left
maternal primiparity, BMI and plasma AGP, and maternal weekly
weight gain, placental weight, duration of pregnancy, and newbornLAZ as direct, statistically significant predictors of newborn WAZ
(Table 3, Model 3). The fully adjusted multivariable model explained
64.1% of the variance in WAZ.
Newborn LAZ was positively associated with maternal height and
Hb concentration at enrolment and negatively associatedwithmaternal
primiparity, HIV infection, peripheral bloodmalaria parasitemia at enrol-
ment, and dental periapical infections (Table 3, Model 4). Adjusting the
analysis further with the potential intermediary variables removed the
association with Hb and malaria and attenuated the other coefficients.
Of the potential intermediary variables, maternal plasma AGP
concentration, weekly weight gain, placental weight, and duration of
pregnancy, but not maternal salivary cortisol concentration, were all
directly associated with newborn LAZ (Table 3, Model 5). The model
explained 34.3% of the variance in LAZ.
In the regression analyses, newborn LAZ andWAZ were thus both
directly predicted by maternal primiparity and four of the predefined
intermediary variables, that is, the duration of pregnancy, placental
weight, maternal plasma AGP, and maternal weight gain during preg-
nancy. Newborn LAZ was additionally predicted by maternal height,
dental periapical infections, and HIV infection (p = .058), whereas new-
born WAZ was predicted by maternal BMI at enrolment and newborn
LAZ but not directly by maternal infections.3.3 | Pathways of causality
A pathway map, obtained from SEM and illustrating both the direct
and indirect predictors of newborn size and coefficients between var-
iables, is shown graphically in Figure 2. As with the regression models,
newborn WAZ was directly predicted by newborn LAZ and maternal
TABLE 2 Multivariable regression model coefficients for predictors of the intermediary outcome variablesa
Intermediary outcome variable
Predictor/intermediary variable
Plasma
AGP
Salivary cortisol
28 weeks
Weekly weight
gain
Placental
weight
Duration of
pregnancy
Maternal ageb (year) −0.022a −0.055 0.048 −0.004 0.013
Maternal primiparityb 0.374*** 0.016 −0.145 −0.122 −0.026
Maternal heightb (cm) −0.016 0.007 0.106*** 0.103** 0.014
Maternal BMIb (kg/m2) −0.028 −0.010 −0.141*** 0.099** −0.056*
Maternal Hbb (g/L) −0.036 −0.001 0.061* −0.069* 0.104***
Maternal HIV infectionb 0.431*** 0.027 −0.235** −0.205* 0.024
Maternal malaria infectionb 0.476*** −0.063 −0.118a 0.085 −0.134*
Maternal periapical infectionsc 0.013 0.000 −0.148* 0.091 −0.216*
Maternal urinary tract infectionc 0.072 0.293 −0.089 0.138 −0.440*
Maternal trichomoniasisc 0.172a −0.042 −0.096 −0.058 −0.153
Placental malaria infectionc 0.123a 0.037 −0.143* 0.068 0.060
Severe chorioamnionitisc −0.260** 0.001 0.030 −0.017 −0.349*
Maternal plasma AGP concentrationb (g/L) N/A 0.030 0.093** −0.054 −0.019
Maternal salivary cortisol concentrationd (nmol/L) 0.027 N/A −0.057a −0.006 −0.001
Maternal weekly weight gaine (g/week) 0.085** −0.057a N/A 0.078* 0.024
Placental weightc (g) −0.050 −0.006 0.079* N/A 0.280***
Duration of pregnancye (week) −0.019 −0.001 0.026 0.299*** N/A
Adjusted coefficient of determinationf (R2; %) 15.4 5.5 7.4 12.4 15.1
Note. Hb = haemoglobin; AGP = α‐1‐acid glycoprotein; BMI = body mass index.
aValues are β coefficients unless otherwise specified.
bMeasured at study enrolment.
cmeasured at delivery or soon thereafter.
dmeasured at 28 gestation weeks.
emeasured throughout the pregnancy.
fproportion of the dependent variable explained by the independent variables in the model, adjusted for the number of independent variables in the model.
*.01 ≤ p < .05.
**.001 ≤ p < .010.
***p < .001.
#.050 ≤ p < .100.
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intermediary variables were directly associated both with WAZ and
LAZ, but the coefficients were bigger for LAZ. Maternal height and
dental periapical infections predicted newborn LAZ directly but WAZ
only indirectly through newborn LAZ or maternal weight gain or pla-
cental weight. All the other test variables shown in the concept map
were associated with newborn WAZ indirectly, sometimes through
several pathways (Figure 2). The indicated model had a good fit
(RMSEA = 0.044, CFI = 0.958, TLI = 0.918), and it explained 32.8%
of the variance in newborn WAZ.
Random forest models, including all the tested predictor and inter-
mediate variables, confirmed the importance of newborn LAZ, duration
of pregnancy, and placental weight as immediate predictors of new-
born WAZ (Figure 3). When these variables were included in the
model, each of the other variables accounted for less than 1.5% of
the prediction accuracy for the newborn WAZ model. The duration
of pregnancy and placental weight was the strongest predictors of
newborn LAZ, but there were seven additional variables (including
maternal height and placental malaria) that each accounted for at least
1.5% of the prediction accuracy for the newborn LAZ model (Figure 3).4 | DISCUSSION
The current analysis was done to characterize the determinants of
newborn size in a rural Malawian setting, using newborn WAZ as the
main indicator and newborn LAZ as a secondary size variable. In a sam-
ple of 1,179 pregnant women, newborn WAZ was directly predicted
by maternal primiparity, BMI and plasma AGP concentration at enrol-
ment, gestational weight gain, duration of pregnancy, placental weight,
and newborn LAZ. The latter five variables were interconnected and
predicted also by more distal determinants, so that newborn WAZ
was ultimately associated with a wide range of variables reflecting
maternal nutrition, infection, inflammation, and some constitutional
factors including parity and height.
The methodological strengths of the study include a prospective
study design, comprehensive data collection that included both clinical
and laboratory variables, implementation in an area with high preva-
lence of preterm birth and low birthweight, and rigorous quality assur-
ance in data collection. Internal validity could have been compromised
by missing data, the delay in anthropometric measurements of some
participants, and the choice of modelling techniques. External validity
TABLE 3 Direct predictors of newborn LAZ and WAZ; results from multivariable regression modelsa
Predictor/intermediary/outcome variable/R2
Newborn WAZ‐score Newborn LAZ‐score
Model 1 Model 2 Model 3 Model 4 Model 5
Maternal ageb (year) 0.031 0.007 0.006 0.028 0.002
Maternal primiparityb −0.385*** −0.287*** −0.139* −0.373*** −0.285**
Maternal heightb (cm) 0.217*** 0.138*** 0.024 0.288*** 0.220***
Maternal BMIb (kg/m2) 0.065* 0.075** 0.053* 0.030 0.043
Maternal Hbb (g/L) 0.090** 0.024 0.024 0.068* −0.001
Maternal HIV infectionb −0.193* −0.039 0.046 −0.305** −0.164#
Maternal malaria infectionb −0.225** −0.125* −0.072 −0.195** −0.102
Maternal periapical infectionsc −0.193* −0.133* −0.025 −0.271** −0.207**
Maternal urinary tract infectionc −0.452* −0.344* −0.186 −0.405a −0.305
Maternal trichomoniasisc −0.167a −0.08 −0.075 −0.081 −0.009
Placental malaria infectionc −0.091 −0.055 −0.010 −0.112 −0.085
Severe chorioamnionitisc −0.096 −0.063 −0.020 −0.118 −0.083
Maternal plasma AGP concentrationb (g/L) −0.107*** −0.056* −0.099**
Maternal salivary cortisol concentrationd (nmol/L) 0.017 0.012 0.011
Maternal weekly weight gaine (g/week) 0.090*** 0.051** 0.075**
Placental weightc (g) 0.303*** 0.181*** 0.236***
Duration of pregnancye (week) 0.680*** 0.342*** 0.652***
Newborn LAZ‐score 0.519***
Adjusted coefficient of determination (R2; %)f 13.5 43.5 64.1 13.6 34.3
Note. WAZ = weight‐for‐age Z‐score; LAZ = length‐for‐age Z‐score; Hb = haemoglobin; AGP = α‐1‐acid glycoprotein; BMI = body mass index.
aValues are β coefficients unless otherwise specified.
bMeasured at study enrolment.
cMeasured at delivery or soon thereafter.
dMeasured at 28 gestation weeks.
eMeasured throughout the pregnancy.
fAdjusted coefficient of determination = proportion of the dependent variable explained by the independent variables in the model, adjusted for the number
of independent variables in the model.
*.01 ≤ p < .05.
**.001 ≤ p < .010.
***p < .001.
#.050 ≤ p < .100.
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way analyses and by the relative under‐representation of primiparous
women in the sample. However, the excluded participants and those
with missing data had on average similar baseline characteristics to
participants who provided data, and we used multiple imputations to
estimate the missing values in regression and SEM. We also included
in our models variables that had been considered appropriate in earlier
analyses (Bhutta et al., 2013; Brodsky & Christou, 2004; Goldenberg,
Culhane, Iams, & Romero, 2008) and employed up‐to‐date statistical
methods to examine relationships between several variables simulta-
neously (DiLalla, 2008). Finally, the results were robust to sensitivity
analyses with random forest modelling. Therefore, although the data
incompleteness certainly reduces the precision of our model estimates,
we believe that the findings are valid and reliable and can be used to
infer causal pathways associating the indicated exposures to newborn
size in the population from which the sample was drawn.
A small newborn size can result from a preterm birth or a restricted
foetal growth velocity or a combination of these two. Maternal
nutrition, reproductive tract infections, chorioamnionitis, malaria,inflammation, and stress have been associated with preterm birth and
hence small newborn size in low‐income settings in previous studies
(Goldenberg et al., 2008). Factors associated with foetal growth restric-
tion have typically included maternal anaemia, undernutrition, HIV and
malaria infections, placental pathology, and foetal factors such as
multiple gestation, genetic aberrations, or congenital viral infections
(Brodsky & Christou, 2004; Hendrix & Berghella, 2008; Resnik, 2002).
Our results corroborate these earlier findings and provide a model of
how a multitude of factors jointly contribute to newborn size in one
rural population in sub‐Saharan Africa.
One important finding from our study was the prominent role of
infections in predicting newborn LAZ and hence indirectly also new-
born WAZ. There are at least three possible mechanisms that might
explain these associations. First, a local inflammatory response can
weaken amniotic membranes and causes their premature rupture and
preterm labour (Goldenberg et al., 2008). Second, inflammation typi-
cally activates prostaglandin synthesis, which may lead to increased
contractibility of the uterus and softening and shortening of the cervix,
also inducing preterm labour (Challis, Matthews, Gibb, & Lye, 2000).
FIGURE 2 Pathway model for the determinants of newborn weight‐for‐age Z‐score (WAZ) and length‐for‐age Z‐score (LAZ). A structural equation
model (structural equation modelling [SEM]), using variables that in regression analyses were associated with (p < .05) newborn size (green boxes) or
defined intermediary variables (orange boxes). The predictor variables represent maternal nutrition (blue boxes), infections (yellow), or other
constitutional variables (grey). The model χ2(36) = 117.92 (p < .001), N = 1,179 participants. Hb = haemoglobin; AGP = α‐1‐acid glycoprotein;
BMI = body mass index
FIGURE 3 Random forest modelling of newborn weight‐for‐age Z‐score (WAZ) and length‐for‐age Z‐score (LAZ). In random forest modelling
newborn LAZ, duration of pregnancy and placental weight are immediate predictors of newborn WAZ (Panel A—black bars), and Newborn LAZ
was most strongly predicted by the duration of pregnancy and placental weight (Panel B—grey bars). AGP = α‐1‐acid glycoprotein; BMI = body
mass index; gw = gestation weeks
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bs_bs_bannerThird, infections can elicit a systemic inflammation that can restrict
foetal growth at least through a reduction in placental vascularization
or a diminished nutrient or oxygen transfer (Boeuf et al., 2013; Conroy
et al., 2013).
In addition to its effects on placental vascularization and function,
systemic inflammation has been shown to alter a hormonal pathway
that drives the elongation of long bones in human fetuses and children.
In a normal pregnancy, foetal growth is largely driven by peptide‐
hormones called insulin‐like growth factors (IGFs) that are secreted by
maternal tissues, the placenta, and the fetus (Woods, Camacho‐Hubner,
Savage, & Clark, 1996). Both maternal and placental infection can be
associated with downregulation of IGF expression in the placenta, low
IGF concentrations in maternal, amniotic cord and newborn plasma,
and higher concentrations of specific binding proteins that inactivateIGFs in foetal circulation (Dimasuay, Boeuf, Powell, & Jansson, 2016).
These effects are at least partially mediated by pro‐inflammatory
cytokines, such as IL‐1, IL‐6, and TNF‐alpha that interrupt signal
transduction for IGF expression and can cause chondrocyte death in
the growth plates of long bones (Hsiao & Patterson, 2011; Walters &
Griffiths, 2009). The critical role of IGFs in foetal growth restriction
has been confirmed in murine and rabbit models, where overexpression
of the IGF‐1 gene in placental tissue has prevented experimentally
induced intrauterine growth restriction in the fetus (Jones,
Crombleholme, & Habli, 2013; Keswani et al., 2015).
The presented pathway model explained only one third of the
variation in the study sample's newborn WAZ. This may be related to
the lack of data on several exposures that have been shown to influ-
ence foetal growth or the duration of pregnancy, such as maternal
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and nutrient intake during pregnancy, vascular disease, pre‐eclampsia
and placental insufficiency, gestational diabetes, phospholipid‐immu-
nity, bacterial vaginosis, genetics, and smoking or alcohol consumption
during pregnancy (Goldenberg et al., 2008). Furthermore, we did not
use repeated measurements, even for variables that are likely to
undergo changes during pregnancy. Because of these limitations, the
presented model cannot be considered a complete picture of newborn
size determinants, even in the study sample. Nevertheless, it presents
a template for how maternal infections, inflammation, undernutrition,
and certain constitutional factors can jointly influence newborn weight
in rural Malawi.
Because of the complex network of adverse exposures, it is not
surprising that tightly focused antenatal interventions targeting only
maternal nutrition or specific infections have at best had only
modest impacts on foetal growth or duration of pregnancy in low‐
income settings (Ashorn, Vanhala, Pakarinen, Ashorn, & De Costa,
2015; Bhutta et al., 2013). For a greater impact, it is likely that more
comprehensive interventions will be needed, to ensure good
nutritional status for the mother both before and during pregnancy,
prevention and treatment of a wide range of maternal infections
and possibly also the prevention of maternal stress. Promotion of
good nutrition is already included in guidelines for antenatal care,
but infection control in low‐income settings typically covers only
malaria, HIV, and syphilis treatment. To further limit the impact of
infection, the current study suggests that severe chorioamnionitis
and maternal dental infections should also be targeted. There is,
however, no reason to believe that this list of infections is exhaus-
tive. Additional maternal infections that could be targeted during
antenatal care could include for instance urinary tract infections,
vaginal trichomoniasis, intestinal parasites, influenza, other viral
infections, and environmental enteric dysfunction (Fell et al., 2017;
Tellapragada et al., 2016). Further studies should be conducted to
identify viral, parasitic, or bacterial infections that elicit systemic
inflammation in pregnant women and contribute to adverse
newborn outcomes in low‐income settings.
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